垂体后叶素辅助治疗肝硬化伴EGVB的效果

The Effect of Pituitrin in the Treatment of Cirrhosis With EGVB

目的研究垂体后叶素辅助治疗肝硬化伴EGVB的效果。方法选取医院2018年3月-2019年2月收治的150例肝硬化伴ECVB为研究对象,使用随机数字表法将其分为试验组(75例)和对照组(75例)。对照组采用生长抑素联合奥美拉唑治疗,试验组采用生长抑素、垂体后叶素和奥美拉唑联合治疗。比较两组临床疗效、门静脉内径、门静脉压、门静脉血流速度和不良反应发生率。结果试验组临床总有效率为89.33%,高于对照组68.00%(P<0.05),门静脉内径、门静脉压、门静脉血流速度低于对照组(P<0.05),两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论生长抑素、垂体后叶素联合奥美拉唑治疗肝硬化伴EGVB的临床效果好,能有效改善门脉压力,且不增加不良反应发生率。

Objective To study the effect of Pituitrin in the treatment of liver cirrhosis with EGVB.Methods From March 2018 to February 2019,150 cirrhotic patients with ecvb admitted to our hospital were selected as the study objects.They were divided into the experimental group(75 cases)and the control group(75 cases)by using the random number table method.The control group was treated with somatostatin and omeprazole,while the experimental group was treated with somatostatin,pituitrin and omeprazole.The clinical effect,the diameter of portal vein,the pressure of portal vein,the velocity of blood flow of portal vein and the incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate of the experimental group was 89.33%higher than 68.00%of the control group(P<0.05),and the diameter,pressure and velocity of portal vein were lower than those of the control group(P<0.05).Conclusion Somatostatin,pituitrin and omeprazole are effective in the treatment of cirrhosis with EGVB,which can effectively improve portal pressure without increasing the incidence of adverse reactions.